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Age-related macular degeneration (AMD), a progressive 
degenerative disease of the retina, is a leading cause of 
blindness in the elderly in industrialized countries.[1-3] It 
is believed to be rare in blacks.[4] However, community-
based studies involving black populations have recently 
shown that the disease is not as rare in blacks as had been 
thought. [5,6] Nonetheless, the frequency in blacks compared 
with the white population is slightly lower.[5]
In the Baltimore Eye Survey, a population-based study 
involving blacks and whites, Friedman et al.[5] reported 
that drusen was common in both blacks and whites over 
the age of 40 years, but the more severe forms of AMD was 
more prevalent in whites. However, the authors admitted 
that they may have underestimated the true incidence of 
AMD among blacks. On the other hand, Klein et al.,[6] 
studying a multiracial United States population, reported 
that the incidence of AMD (including all early and late 
lesions) was not significantly different among non-Hispanic 
blacks, Mexican-Americans, and non-Hispanic whites. 
Original Article
Abstract
Objectives: To determine the incidence, pattern and ocular morbidity associated with age-related macular degeneration 
(AMD) at the Guinness Eye Center Onitsha Nigeria.
Materials and Methods: The case files of all new patients aged 50 years and above seen between January 1997 
and December 2004 were reviewed. The files of patients with AMD were further studied. Information on age, gender, 
occupation, duration of symptoms, type of maculopathy, visual acuity, ocular and systemic co-morbidities were abstracted 
into a standard proforma and analyzed using the chi-square test, student t-test and confidence interval estimation.
Results: Two hundred and fifty-six of 7966 (3.2%) new patients had AMD; M:F = 2:3; 60 -79 year age group constitute 
70% of the cases. Non-neovascular AMD occurred in 210 (82%) patients with 182 (71.1%) having early AMD and 
28 (10.9%) geographic atrophy. Neovascular AMD occurred in 46 (18%) patients. AMD was bilateral in 221 (86.3%) 
patients. Most patients presented late. Systemic co-morbidities were hypertension and diabetes; the main ocular co-
morbidities were cataract and glaucoma. Thirty-four (13.3%) patients were bilaterally blind and130 (50.8%) had bilateral 
visual impairment. Of the blind patients 13(38.3%) had neovascular AMD and 6 (17.7%) had geographic atrophy. This 
makes AMD the cause of blindness in 7.4% of the patients. An affected eye was more likely to have low vision than an 
unaffected eye (95%CI: 0.07, 0.21; P<0.05); persons aged 70 years and above were more likely to be blind (χ2 – 7.26, 
df -1; P<0.05); females were also more likely to be blind than males (t – 2.857, df – 8; P<0.05) and neovascular AMD 
significantly causes more blindness than the non-neovascular type (95% CI: 0.11, 0.37; P<0.05).
Conclusions: AMD was the main cause of blindness in 7.4% of the patients. Treatment facilities including low vision 
aids for AMD patients should be provided in eye hospitals in Nigeria. Health education of the public highlighting the risk 
factors for AMD should be mounted as part of Vision 2020 programme in Nigeria. A community based study is required 
to fully define the epidemiologic characteristics of AMD in Nigerians.
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In the Barbados Eye Study, Schachat et al.[7] reported an 
increased prevalence of AMD. Compared with the blacks in 
the Baltimore Eye Study, blacks in the Barbados Eye Study 
had higher rates of AMD and pigmentary abnormalities.[5]
In Nigeria, hospital-based studies have documented the 
contribution of AMD to the burden of blindness and 
low vision.[8-10] Although Ayanru[8] reported the rarity of 
the disease in Benin-City, Abiose[9] and later Nwosu[10] 
separately documented that AMD was the commonest 
retinal disease in Lagos, south-western Nigeria and Onitsha, 
south-eastern Nigeria, respectively.
Nevertheless, the detailed information on the pattern 
and epidemiologic characteristics of AMD in Nigerians 
is essentially lacking. The aim of the present study is to 
determine the incidence, pattern, and ocular morbidity 
associated with AMD over an 8-year period at the Guinness 
Eye Center, Onitsha, Nigeria.
Materials and Methods
This is a retrospective study. The case files of all new patients 
aged 50 years and above seen at the Guinness Eye Center 
Onitsha, Nigeria, between January 1997 and December 
2004 were reviewed. The files of patients with AMD were 
further studied. Information on age, gender, occupation, 
duration of symptoms, type of maculopathy, visual acuity, 
ocular, and systemic comorbidities were filled into a standard 
proforma and analyzed.
AMD was graded according to the international 
classification and grading system,[11] which defined the 
disease as a degenerative disorder of persons ≥50 years 
of age that is characterized by the following abnormalities 
in the macula: soft large drusen, hyperpigmentation and/
or hypopigmentation of the retinal pigment epithelium 
and associated neurosensory detachment, (peri)retinal 
hemorrhage, geographic atrophy of the retinal pigment 
epithelium, or (peri)retinal fibrosis in the absence of other 
retinal vascular disorders. Specifically, the early AMD, 
also known as age-related maculopathy (ARM), applies to 
the presence of drusen and any of the pigment epithelial 
abnormalities, while late features of the disease include 
geographic atrophy, pigment epithelial detachment, 
choroidal neovascularization, and disciform scar. The late 
AMD with neovascularization and disciform scar is also 
known as neovascular or wet or exudative AMD, while late 
manifestation not associated with new vessel formation is 
known as atrophic or dry or non-neovascular AMD.
Blindness was defined as presenting visual acuity <3/60, 
while a presenting acuity <6/18 – 3/60 was regarded as 
visual impairment. In deciding the cause of blindness or 
visual impairment in an eye with more than one ocular 
pathology, the more advanced lesion is taken as the cause 
of the morbidity. For instance, in an eye with neovascular 
AMD coexisting with immature cataract, neovascular 
AMD is taken as the cause of blindness, whereas in an eye 
in which early AMD coexisted with advanced glaucoma, 
the latter is taken as the cause of the blindness. For the 
patient, the cause of blindness or visual impairment in the 
last affected eye is taken. Chi square test, student t-test, 
and 95% confidence interval estimation were used to test 
the relationship between the different variables with the 
alpha level at 0.05.
Results
During the study period, 7 966 new patients aged 50 years 
and above were seen in our hospital. Of this number, 256 
patients had AMD. This gives an incidence of 3.2% (95% 
CI: 2.8, 3.4). However, the annual incidence as shown in 
Table 1 varied from 1.7% (1997) to 4.1% (2000). There were 
102 male and 154 female patients (M : F = 2 : 3). The age 
range was 50 to 91 years with the 60 to 79 year age group 
constituting nearly 70% of the cases. Table 2 shows the age 
and sex distribution of the patients. There was no difference 
between the ages of the male and female patients (t – 1.537; 
df – 8; 95%CI: -0.02, 0.22; P>0.05).
Non-neovascular (dry) AMD occurred in 210 (82%) 
patients, with 182 (71.1%) having early AMD and 
28 (10.9%) having geographic atrophy. Neovascular 
(exudative) AMD was found in 46 (18%) patients. In 
other words, 182 (71.1%) had the early form of the 
disease, while 74 (28.9%) had the late or advanced 
disease (neovascular disease and geographic atrophy). 
Table 1: Annual hospital incidence of AMD
Year All patient AMD patients Incidence (%)
1997 1 100 19 1.7
1998 990 38 3.8
1999 920 37 4.0
2000 840 34 4.1
2001 1 280 48 3.8
2002 1 040 19 1.8
2003 1 180 38 3.2
2004 616 23 3.7
Total 7 966 256 3.2
AMD = Age-related macular degeneration
Table 2: Age and sex distribution
Age (years) Male Female Total %
50–59 31 32 63 24.6
60–69 26 63 89 34.8
70–79 33 55 88 34.4
80–89 10 4 14 5.4
90+ 2 - 2 0.8
Total 102 154 256 100.0
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Although 221 (86.3%) patients had bilateral disease, 35 
(13.7%) patients had monocular disease. The duration 
of symptoms ranged from one month to 14 years with 
70% presenting more than one year after the onset of 
symptoms.
Table 3 shows the systemic and ocular comorbidities. 
Hypertension and diabetes mellitus were the systemic 
comorbidity, while cataract and glaucoma were the main 
coexisting ocular diseases. Table 4 shows the presenting 
visual acuity in both the affected and the unaffected eyes 
of the patients. No patient had a visual acuity of 6/6 in the 
affected eye. Thirty-four patients (13.3%) were bilaterally 
blind and 130 (50.8%) patients had bilateral visual 
impairment. AMD was not the sole cause of blindness in 
all the patients. The causes of blindness were neovascular 
AMD, 13 (38.3%); cataract, 7 (20.6%); geographic atrophy, 
6 (17.7%); glaucoma, 4 (11.8%); myopia, 2 (5.8%); and 
central leukoma, 2 (5.8%). Thus, AMD caused blindness 
in 19 (7.4%) of the patients.
An affected eye was more likely to have low vision than an 
unaffected eye (95%CI: 0.07, 0.21; P<0.05). Persons aged 
70 years or above were more likely to be blind (c2 – 7.26, df 
-1; 95%CI: 0.06, 0.26; P<0.05). Females were also more 
likely to be blind than men (t – 2.857, df – 8; 95% CI: 0.04, 
0.40; P<0.05). Neovascular AMD significantly causes more 
blindness than the non-neovascular type (95% CI: 0.11, 
0.37; P<0.05).
Discussion
The prevalence and incidence of AMD are generally taken 
to be very low among blacks, especially when compared with 
Caucasians.[4] The incidence (3.2%) recorded in the present 
study, though lower than that of cataract,[12] is certainly 
higher than that of childhood blindness,[13] domestic eye 
injuries,[14] or diabetic retinopathy,[15] as recorded in the 
same environment during the same period of time.
In a review of AMD in Benin-City, Omoti[16] reported an 
incidence of 5% which is higher than that obtained in the 
present study. The reason for this disparity may be related 
to the population studied and the study duration. Although 
the present study was restricted to patients aged 50 years 
and above, Omoti studied patients aged 1 month to 104 
years. Similarly, although the present study analyzed patients 
seen over an eight-year period, the Benin-City study was 
restricted to only two years.
In our hospital, AMD is the commonest retinal disease 
and the third most common eye disease in the elderly after 
cataract and chronic simple glaucoma.[17] Therefore, AMD 
as a cause of ocular morbidity should be seriously considered 
when planning eye care for the elderly in our environment.
Earlier reports had speculated on the possible role of diet and 
toxins in the etiology of AMD in Nigerians.[8] Further studies 
are definitely required to explore the possible roles of cassava 
(a Nigerian dietary staple known to contain cyanide); chronic 
malarial infection; and locally brewed alcoholic beverages on 
the development of AMD and other retinal diseases.
Cigarette smoking is a known risk factor for AMD,[18] 
but its role was not determined in the present study. 
Some young and middle-aged Nigerians smoke cigarette, 
although inhalation of tobacco snuff and smoking of dry 
tobacco leaf are more prevalent among the elderly. The 
Age-Related Eye Disease Study had reported that among 
persons with early or intermediate AMD, smoking and 
body mass index were modifiable risk factors associated 
with progression to advanced AMD.[18] The inability to 
determine the proportion of the present cohort of patients 
who consume cigarette or tobacco is one of the weaknesses 
of a retrospective study.
Hypertension and diabetes were the two systemic 
comorbidities in the patients, while cataract and glaucoma 
were the main ocular diseases coexisting with AMD in the 
patients studied. These systemic and ocular comorbidities 
have deleterious effects on the eye. In addition, hypertension 
is a risk factor for AMD.[19,20] In the Beaver Dam Eye Study, 









Retinal vein occlusion 4 1.6
Refractive error 4 1.6
Others (PVD, leukoma, etc) 15 5.9
PVD = Posterior vitreous detachment
Table 4: Presenting visual acuity of AMD eyes












AMD = Age-related macular degeneration
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it was reported that after controlling for other factors, 
persons with controlled hypertension at baseline were 
about twice as likely, while persons with uncontrolled 
hypertension were thrice as likely to develop exudative 
macular degeneration.[19] Other studies have also linked 
moderate to severe hypertension to exudative AMD.[20] 
Neovascular (exudative) AMD is the commonest cause 
of blindness among patients in the present study. Similar 
to the experience in developed countries,[21] cataract and 
glaucoma were also important causes of blindness in these 
patients. Therefore, the comorbidities need to be treated 
early and factors predisposing to them modified so as to 
minimize vision loss in the patients.
This study detected a gender difference in blindness rate 
with females being more likely to be blind from AMD than 
their male counterparts. Previous studies on the prevalence 
of blindness had reported this trend[12] and the low priority 
given to issues concerning women blamed. Therefore, 
this finding should further reinforce the need to institute 
programs aimed at improving the lot of women in Nigeria.
Neovascular AMD was found in 18% of our patients. This is 
higher than the 10.9% found to have geographic atrophy. In 
his study, Omoti[16] reported that “pure geographic atrophy” 
was commoner than “pure neovascular’’ AMD. Again, this 
difference may have been influenced by the criteria used in 
defining AMD. Omoti defined it as “pure” when the lesion 
is present in both eyes. Omoti’s definition differs from the 
International Classification and Grading System of AMD. [11] 
On the other hand, the present study strictly adopted the 
International Classification and Grading System of AMD.[11]
Neovascular disease must have been underdiagnosed in the 
patients since fluorescein and indocyanine angiographic 
facilities were not available in our hospital at the time of 
the study. Nonetheless, it was the most frequent cause of 
blindness in this cohort. This is in consonance with findings 
in Caucasians.[21] Recent advances have demonstrated the 
effectiveness of laser including photodynamic therapy[22] 
and pharmacotherapy such as antivascular endothelial 
growth factors (pegaptanib, ranibizumab, etc.)[23,24,25] in 
the treatment of neovascular AMD. These new treatment 
modalities need be made available and affordable in 
government hospitals for the benefit of the patients.
On the other hand, the effectiveness of the prophylactic use 
of antioxidants in early AMD has been demonstrated.[26] 
This information should be made known to the public who 
should also be educated on the risk factors for AMD. Low 
vision in the patients should be managed with appropriate 
low vision aids as part of rehabilitation of the visually 
challenged in the society. Nearly 60% of the patients in this 
study [Table 2] are within the economically productive age 
group and therefore, their loss of productivity through severe 
uncorrected low vision is an avoidable waste.
As health services improve, HIV/AIDS controlled, and the 
standards of living improve, the population of the aged in 
Nigeria will expectedly rise. Currently, cataract treatment 
is justifiably the focus of blindness prevention efforts. 
However, the results of this study point to the need to also 
pay attention to AMD in order to minimize the associated 
ocular morbidity. A community-based study would also be 
required to fully define the epidemiologic characteristics of 
AMD in Nigerians.
Conclusions
AMD was the main cause of blindness in 7.4% of the 
patients. This is comparable with the 8.6% recorded by 
Omoti[11] in Benin City. Therefore, treatment facilities 
including low vision aids for AMD patients should be 
provided in eye hospitals in Nigeria. Health education of 
the public highlighting the risk factors for this important 
cause of blindness in the elderly should also be mounted as 
part of Vision 2020 programme in Nigeria.
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